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Abstract
Background: Risk models are used to calculate the likelihood of carrying a BRCA1 or BRCA2
mutation. We evaluated the performances of currently-used risk models among patients from a
large familial program using the criteria of high sensitivity, simple data collection and entry and BRCA
score reporting.
Methods: Risk calculations were performed by applying the BRCAPRO, Manchester, Penn II,
Myriad II, FHAT, IBIS and BOADICEA models to 200 non-BRCA carriers and 100 BRCA carriers,
consecutively tested between August 1995 and March 2006. Areas under the receiver operating
characteristic curves (AUCs) were determined and sensitivity and specificity were calculated at the
conventional testing thresholds. In addition, subset analyses were performed for low and high risk
probands.
Results: The BRCAPRO, Penn II, Myriad II, FHAT and BOADICEA models all have similar AUCs
of approximately 0.75 for BRCA status. The Manchester and IBIS models have lower AUCs (0. and
0.47 respectively). At the conventional testing thresholds, the sensitivities and specificities for a
BRCA mutation were, respectively, as follows: BRCAPRO (0.75, 0.62), Manchester (0.58,0.71), Penn
II (0.93,0.31), Myriad II (0.71,0.63), FHAT (0.70,0.63), IBIS (0.20,0.74), BOADICEA (0.70, 0.65).
Conclusion: The Penn II model most closely met the criteria we established and this supports the
use of this model for identifying individuals appropriate for genetic testing at our facility. These data
are applicable to other familial clinics provided that variations in sample populations are taken into
consideration.
Background
Breast cancer is the most frequently diagnosed cancer
among women in North America. Statistics for the year
2007 showed that 1 in 9 women will be diagnosed with
the disease and 1 in 27 women will die of it [1]. Although
the specific etiology of breast cancer is unknown, hormo-
nal, reproductive and hereditary factors have all been
shown to be risk factors.
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Among the hereditary factors involved in breast cancer,
single gene mutations contribute a significant increase in
risk. In 1990, the BRCA1 gene was mapped to chromo-
some 17 by genetic linkage analysis [2], and the BRCA2
gene was subsequently identified and mapped to chromo-
some 13 [3]. Population-based studies have shown that
mutations in BRCA1 and BRCA2 confer an increased risk
of breast, ovarian and other cancers. The syndrome asso-
ciated with BRCA mutations is termed Hereditary Breast
and Ovarian Cancer (HBOC). Most breast cancers known
to be hereditary are attributable to HBOC. Other syn-
dromes such as Li-Fraumeni syndrome [4], PTEN muta-
tion-associated syndromes [5] and heterozygous Ataxia
Telangiectasia [6] account for less than 5% of hereditary
breast cancers.
Cancer risks associated with BRCA1 and BRCA2 muta-
tions have been well documented, but are varied. These
risks probably depend on family history, the population
under study and the mutation type [7]. Most recent risk
estimates from a large United States sample suggest that
breast cancer risks up to age 70 for BRCA1 and BRCA2
mutation carriers are 43% and 46% respectively, and
ovarian cancer risks are 39% and 22% respectively [8].
However, there are discrepancies in risk estimates, as pre-
vious studies have shown breast cancer risks of 56–87%
[9] and ovarian cancer risks of 10–40% [10]. Also, there
may be increased risks of other cancers such as male breast
cancer [11], melanoma, pancreas and prostate cancer
associated with BRCA mutations [12].
Various methodologies have been developed to identify
mutations in BRCA1 and BRCA2, and numerous studies
have been performed to evaluate the benefits and limita-
tions of each method. In the United States, testing is com-
monly performed by gene sequencing and large deletion
and rearrangement screening [13]. In other areas of the
world, denaturing high performance liquid chromatogra-
phy (DHPLC) is the method used for detecting mutations
[14]. In Ontario, Canada, the testing methodology
changed in 2007 from protein truncation testing (PTT)
with sequencing of exons 2 and 5 of BRCA1, to the cur-
rently-used DHPLC and multiplex ligation-dependent
probe assay (MLPA) [15,16].
Individuals with known BRCA mutations are managed
differently from the general population. Mutation carriers
are offered intensified surveillance for early detection,
chemoprevention and risk-reducing surgeries. Knowledge
of a hereditary predisposition can significantly alter med-
ical management and follow-up for carriers, regardless of
previous cancer history [17], and may allow access to
healthcare resources not widely available to individuals at
general population risk.
Patients gain access to BRCA testing through familial can-
cer genetics programs. Health care providers refer patients
to these programs because of a family history of cancer.
Given that funding for genetic testing is limited and that
BRCA mutations are rare even in the referred population,
the challenge remains to identify those individuals most
likely to carry a mutation prior to offering genetic testing.
A family history assessment is crucial for this process. This
can involve a review of a detailed three-generation pedi-
gree by a specialist, and also a risk calculation using vali-
dated risk assessment models.
The BRCAPRO [18-20], Myriad II [21], Couch (also
known as Penn) [22], Family History Assessment Tool
(FHAT) [23], Manchester [24], Penn II [25], IBIS [26], and
Breast and Ovarian Analysis of Disease Incidence and Car-
rier Estimation Algorithm (BOADICEA) [27,28] models
have all been developed to predict the probability of iden-
tifying germline BRCA mutations in an individual or a
family. BRCAPRO, Myriad II, Couch and FHAT were
among the first risk models developed and have been in
clinical use for a number of years through CaGene soft-
ware. The Manchester, Penn II, IBIS and BOADICEA mod-
els were developed more recently. Each model calculates
risk on the basis of the inclusion of different cancer diag-
noses within a family. All models incorporate a family his-
tory of breast and ovarian cancer. In addition, the FHAT
includes colon and prostate cancer, while the Manchester,
BOADICEA and Penn II models include prostate and pan-
creatic cancer. The IBIS model only includes female diag-
noses of breast and ovarian cancer (Table 1).
Although BRCA testing in Ontario, Canada is often based
on guidelines developed by the Ministry of Health and
Long-Term Care (MOHLTC), risk assessments prove use-
ful when eligibility is not clear. This study was planned to
evaluate all the available risk assessment models in order
to identify the model or models that will be of most ben-
efit in our population. We established the following crite-
ria for assessing the models. The most appropriate model
should have:-
1. At least 90% sensitivity to capture as many BRCA muta-
tion carriers as possible. To establish high sensitivity, a
lower specificity is acceptable because the test carries few
negative consequences.
2. Applicability to as many probands as possible regard-
less of cancer status, sex or degree of cancer history in the
family.
3. A tendency towards easy and efficient data collection
and entry.BMC Medical Genetics 2008, 9:116 http://www.biomedcentral.com/1471-2350/9/116
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4. Overall BRCA risk scores as well as individual BRCA1
and BRCA2 risk scores, because in Canada, genetic testing
for both these genes is conducted simultaneously rather
than sequentially.
Methods
The area under the receiver operating characteristic (ROC)
curve was selected as the main summary of each model's
ability to discriminate between patients with and without
a mutation. To obtain an adequate sample size, a retro-
spective case-control design was utilized. Sample size cal-
culations using PASS 2002 [29] demonstrated that 100
carriers and 200 non-carriers provided estimates of the
area under the ROC curve with confidence interval half-
widths of 0.06 to 0.07 over a range of possible true areas,
and that increasing the sample size provided little addi-
tional benefit. The term 'carriers' is used to describe
BRCA1 or BRCA2 mutation carriers, and the term 'non-
carriers' is used to describe individuals who have no muta-
tion in BRCA1 or BRCA2.
The Familial Breast Cancer Clinic at Mount Sinai Hospital
in Toronto (Canada) receives referrals of probands due to
a family history of breast and/or other cancers, or because
of a concern about breast cancer risk. Referrals originate
from oncologists, surgeons, general practitioners, gyne-
cologists and other healthcare specialists. Referred indi-
viduals complete a family history questionnaire prior to
their first visit to the clinic. A three generation pedigree is
constructed using this questionnaire and a personal inter-
view with a genetic counsellor or nurse practitioner.
Where applicable, medical records are obtained to verify
cancer diagnoses. Subjects' eligibility for genetic testing is
determined on the basis of the MOHLTC testing criteria
(Table 2). Informed consent for genetic testing is obtained
following a session with a genetic counsellor or a medical
geneticist.
Genetic testing
During the study period, genetic testing was performed in
the Molecular Genetics Laboratory of Mount Sinai Hospi-
tal in Toronto, Canada using PTT of BRCA1 and BRCA2
combined with DNA sequencing of exons 2 and 5 in
BRCA1. DNA and RNA were extracted from whole blood
samples and amplified with primers containing linkers to
enable the translation of DNA into proteins. PCR prod-
ucts were converted into proteins by the T7 TNT kit. The
proteins were separated by size on SDS-PAGE gels for
Table 1: Applicability and ease of use of risk assessment models.
Calculation 
method
Cancers included Inclusiveness Family history 
required
Data entry
BRCAPRO CaGene 4.3 software Male and female 
breast and ovarian 
cancer
All individuals 1st and 2nd degree 
relatives
Complete pedigree 
data entered for 
affected and 
unaffected
Myriad II CaGene 4.3 software Male and female 
breast and ovarian 
cancer
All individuals 1st and 2nd degree 
relatives
Data searchable by 
established tables or 
data entry on CaGene 
4.3 software
Couch CaGene 4.3 software Male and female 
breast and ovarian 
cancer
Excludes probands 
from families with 
only ovarian or male 
breast cancer
1st and 2nd degree 
relatives
Data searchable by 
established table or 
data entry on CaGene 
4.3 software
Ontario Family 
History 
Assessment Tool 
(FHAT)
CaGene 4.3 software Male and female 
breast, ovarian, colon 
(<50 yrs), prostate 
cancer (<50 yrs)
All individuals 1st and 2nd degree 
relatives
Data searchable by 
established table or 
data entry on CaGene 
4.3 software
Manchester Hand calculations Male and female 
breast, ovarian, 
prostate and 
pancreatic cancer
Excludes Ashkenazi 
Jewish
1st, 2nd, and 3rd degree 
relatives
Scoring system
Penn II Web-based Male and female 
breast, ovarian, 
prostate and 
pancreatic cancer
Excludes probands 
from families with no 
breast cancer cases
1st, 2nd, and 3rd degree 
relatives
One page 
questionnaire
IBIS Down-loadable 
software
Female breast and 
ovarian cancer
Includes only females 
unaffected by breast 
cancer
1st, 2nd, and 3rd degree 
relatives
One page 
questionnaire
BOADICEA Web-based Breast, ovarian, 
prostate and 
pancreatic cancer
All individuals 1st, 2nd, and 3rd degree 
relatives
Complete pedigree 
data entered for 
affected and 
unaffectedBMC Medical Genetics 2008, 9:116 http://www.biomedcentral.com/1471-2350/9/116
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comparison. Mutation identification was verified using
DNA sequencing.
Heteroduplex analysis is used for individuals who qualify
for the Ashkenazi Jewish (AJ) screen by MOHLTC criteria.
Mutations tested for are 185delAG, 188del11 and
5382insC mutations in BRCA1, and 6174delT in BRCA2.
Patient population and risk assessment
In May 2006 a chart review of probands who had com-
pleted genetic testing in our clinic was conducted. A
proband is defined as the index case in the family who
serves as a starting point for the study of a pedigree or fam-
ily history. Probands with prior BRCA1  and  BRCA2
genetic testing and known results were included.
Probands who had a known relative with a BRCA1 or
BRCA2  mutation were excluded. Chart access was
approved by the hospital Research Ethics Board (REB).
Two hundred non-carriers, consecutively tested between
October 2001 and March 2006, and 100 carriers, consec-
utively tested between August 1995 and March 2006, were
identified.
During the chart review, risk assessments were performed
on all 300 probands using the three generation pedigrees
obtained prior to genetic testing. BRCAPRO, Myriad II,
Couch and FHAT were calculated using CaGene 4.3 soft-
ware [30]. Penn II scores were calculated using the Penn II
official public web site http://www.afcri.upenn.edu/itacc/
penn2/[25]. The 2007 updated version of this risk assess-
ment software was used in the analysis. The BOADICEA
risks were calculated on-line https://pluto.srl.cam.ac.uk/
cgi-bin/bd1/v1/bd.cgi accessing the most recently availa-
ble version. Values for unknown ages and unknown year
at death were estimated by assuming 25 years between
each generation [31]. The updated Manchester model was
calculated by hand. Scores for unaffected probands were
calculated using a variant form of this model by obtaining
scores for the closest affected relative and using Mendelian
principles based on degree of relatedness to the proband
[24]. IBIS scores were obtained using downloadable soft-
ware. Where the models provided separate BRCA1 and
BRCA2 scores, the scores were added to obtain a total
BRCA score.
The ROC curve was found empirically by calculating sen-
sitivity versus the false positive rate (1 – specificity) for
each possible threshold value, and the area under the
ROC curve (AUC) was obtained using the trapezoidal rule
[32]. Ninety-five percent confidence intervals (CI) for the
AUCs were calculated using the BCa bootstrap method
[33] with 1000 bootstrap samples. For interpretation pur-
poses, note that an AUC of 0.5 is reached by chance alone
while 1 is the maximum. The higher the AUC, the higher
the model's discriminative power.
We calculated empirical estimates of the sensitivity and
specificity for positive BRCA status at the conventional
testing thresholds; 10 was used as threshold for all models
except the Manchester for which a threshold of 15 has
been suggested [24]. In accordance with our criterion of
obtaining a model with high degrees of sensitivity, the
testing threshold at which each model reached 90% sensi-
tivity was used and the corresponding specificity was cal-
culated.
To address the problem of selection and spectrum bias, we
repeated the above calculations separately for low and
high risk probands. Low risk probands were defined as
individuals with no first degree relatives with breast or
ovarian cancer, and high risk probands as individuals
with one or more first degree relatives with breast or ovar-
ian cancer. The AUC was also calculated separately for
probands who were and were not of Ashkenazi Jewish
descent. The IBIS model, applicable only to unaffected
probands, was not used in the subset analyses because the
sample size was too small.
Results
Spectrum of patients studied
Patient characteristics for the case-control sample of 100
carriers and 200 non-carriers are given in Table 3. Approx-
Table 2: Ontario Ministry of Health and Long-Term Care (MOHLTC) criteria for BRCA1 and BRCA2 genetic testing eligibility
Non-Ashkenazi Jewish Ashkenazi Jewish
• Breast cancer <35 years ￿ Breast cancer <50 years
￿ Male breast cancer ￿ Breast cancer at any age with family history
￿ Serous ovarian cancer ￿ Unaffected individual with family history
￿ Breast cancer <60 years and family history of ovarian or male breast cancer
￿ Breast and ovarian cancer in same individual
￿ Bilateral breast cancer
￿ 2 cases breast cancer <50 years
￿ 2 cases ovarian cancer
￿ 3 cases breast cancer any age
￿ Known mutation
￿ Clinical judgmentBMC Medical Genetics 2008, 9:116 http://www.biomedcentral.com/1471-2350/9/116
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imately 35% of patients in both groups (35 carriers and
71 non-carriers) were in the low risk subset as previously
defined. Approximately 40% of probands in both groups
were Ashkenazi Jewish.
Application of models
The applicability of each model is summarized in Table 1.
The BRCAPRO, Myriad II, FHAT and BOADICEA models
were applied to all 300 probands. The Penn II model was
used for all except 3 individuals from families with ovar-
ian cancer only and no breast cancer. The Manchester
model was applied to 181 non-Ashkenazi Jewish individ-
uals. The Couch model was applied to all except 6
probands from families with only ovarian cancer or male
breast cancer. The IBIS model was applicable to 65 female
probands with no prior diagnosis of breast cancer. All
models except the Myriad II, FHAT and Couch provided
separate scores for BRCA1 and BRCA2, which were added
to obtain a total BRCA score. Myriad II and FHAT provide
only a total BRCA score. The Couch model calculates only
BRCA1 probabilities.
Ease of use
For each model, ease of use was judged on the basis of the
data required and the time used for data entry. The BRC-
APRO, Couch, Myriad II and FHAT were calculated using
CaGene 4.3 software, which requires the entire pedigree
to be entered. However, the Couch, FHAT and Myriad II
models can also be used via searchable tables of probabil-
ities, with the tables for Myriad II developed for both
Ashkenazi Jewish and non-Ashkenazi Jewish individuals.
The Manchester model uses a scoring system. The IBIS and
the Penn II models both use a one-page questionnaire
requiring data on affected individuals only. As an exam-
ple, the time taken by an experienced counsellor to enter
the same 3 generation pedigree into each program was cal-
culated. Data entry for BRCAPRO, Myriad II, Couch and
FHAT (using CaGene 4.3 software) took 4 minutes. Data
entry was 40 seconds for the Manchester model, 35 sec-
onds for the Penn II model, 70 seconds for the IBIS model
and 6 minutes for the BOADICEA model. The methods of
data entry are summarized in Table 1.
Measures of performance
The ROC curves for BRCA status for all the models are
shown in Figure 1. The AUCs are shown in Table 4 with
95% confidence intervals. The BRCAPRO, Penn II, Myriad
II, FHAT and BOADICEA models all have similar AUCs of
approximately 0.75 for BRCA status, indicating that these
models have similar discriminating power. The Manchester
and IBIS models have lower AUCs (0.68 and 0.47). As
expected, low risk patients have lower AUCs than high risk
patients. Table 4 also demonstrates that the discriminating
power is higher when only BRCA1 status is considered. All
the models have low discriminating power for BRCA2.
Table 5 shows the sensitivity and specificity for BRCA status
at the conventional testing thresholds. In the full sample,
and for the low risk subset, sensitivities at these conven-
tional testing thresholds are 70% or lower for all models
except the Penn II model, which exceeds 90% sensitivity.
Table 6 demonstrates that when appropriate thresholds are
used, other models can also achieve 90% sensitivity. At
90% sensitivity, Penn II and Myriad II had the highest spe-
cificity in the full sample (approximately 35%).
The following AUCs were obtained for the Ashkenazi Jew-
ish and non-Ashkenazi Jewish subsets respectively: BRC-
APRO (0.77; 0.76), Penn II (0.79; 0.72), Myriad II (0.74;
0.77), FHAT (0.75; 0.74) and BOADICEA (0.74; 0.74).
The Manchester model has an AUC of 0.68 for the non-
Ashkenazi Jewish subset; it does not apply to Ashkenazi
Jewish individuals.
Discussion
Combined with a detailed assessment by a genetic coun-
sellor or geneticist, a complete risk assessment using vali-
Table 3: Characteristics of study population
Carriers
(n = 100)
Non-Carriers
(n = 200)
Carrier status BRCA1: 58% not
BRCA2: 42% applicable
Gender Female: 91% Female: 98%
Male: 9% Male: 2%
Ashkenazi Jewish descent Yes: 39% Yes: 40%
No: 61% No: 60%
Mean age (± standard deviation) 51 years 52 years
(± 12.7) (± 13.5)
Type of cancer Breast: 75% Breast: 73%
Ovarian: 6% Ovarian: 0%
Both: 4% Both: 0%
Not affected: 15% Not affected: 27%
Number of 1st degree relatives with breast or ovarian cancer None: 35% None: 36%
One or more: 65% One or more: 64%BMC Medical Genetics 2008, 9:116 http://www.biomedcentral.com/1471-2350/9/116
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dated models helps to confront the challenge of
identifying the greatest number of carriers while maximiz-
ing the use of limited healthcare funding for genetic test-
ing in both privately and publicly funded healthcare
systems.
Application of models
The IBIS model (which can only be used for unaffected
probands) is of limited use in familial clinics where many
of the individuals undergoing genetic testing have had
breast cancer. Since our clinic has a relatively high propor-
tion of Ashkenazi Jewish individuals, the Manchester
model is of limited utility.
Ease of use
It was the experience of the counsellor performing risk
assessments that the models requiring complete pedigree
data entry took the longest time to complete, and those
requiring a one-page questionnaire, a searchable table of
probabilities or a scoring system took the least time. On
this basis, the BRCAPRO and BOADICEA models required
the most time for data entry. These two models also
required information on the cancer status and age or age
at death of all family members. These data were often dif-
ficult for probands to recall, and this possibly compro-
mised the accuracy of the risk assessment. Models using a
one page questionnaire (Penn II, IBIS), and those with a
scoring system (Manchester) or table review (Myriad II)
took the least time to complete. This is because these
models required limited data on only those family mem-
bers affected by cancer. Often these data were easier for
probands to recall, thus probably decreasing inaccuracies
in calculation.
Testing thresholds
Early publications have advocated the use of a 10% testing
threshold, and risk assessment models have been devel-
oped and validated around this. Our results clearly dem-
onstrate that the widespread use of 10% is not appropriate
for all models, clinics or purposes. Only one model (Penn
II) was able to achieve a high sensitivity (90%) consist-
ently in our population using this conventional testing
threshold. However, the Myriad II had similar sensitivity
and specificity to the Penn II when a threshold of 5.8 was
employed.
Evaluation against criteria
Prior to comparing the models, we developed criteria by
which to assess them. At the recommended testing thresh-
old of 10%, the Penn II model achieved the highest sensi-
tivity in comparison to all other models. The BRCAPRO,
Myriad II, FHAT, Penn II and BOADICEA models were
applicable to most probands. When the same model is
used on all probands, this provides a consistent method
of risk assessment. The least time-consuming models and
the easiest for data entry and collection were the Penn II,
IBIS, Myriad II and Manchester. All except the Couch
model provided combined BRCA scores. Mainly on the
basis of the sensitivity at the recommended testing thresh-
old, but also taking account of wide applicability and ease
of data collection and data entry, we conclude that the
Penn II model is best suited for use in our clinic popula-
tion.
Biases
Multiple methods of genetic testing for BRCA1  and
BRCA2  mutations are available. In this study, protein
truncation testing (PTT) was the methodology used. This
method has a slightly lower sensitivity in finding BRCA1
and  BRCA2  mutations than direct DNA sequencing
[16,34]. Additionally, large gene rearrangements are not
detected by PTT. Other testing techniques such as DHPLC
combined with MLPA are more sensitive and can detect
large gene rearrangements. However, they are also found
to identify a greater number of variants of uncertain signif-
icance (VUS). Counseling and management of individu-
als with VUS remains a clinical challenge.
In a previous study based on a convenience sample of 103
unselected probands from our clinic [25], we also showed
that the proportion of probands meeting the testing
threshold varied by risk model: BRCAPRO (34%), Myriad
II (33%), Manchester (55.3%) and Penn II (46.6%). The
Receiver operator characteristic (ROC) curves for risk  assessment models for BRCA1 and BRCA2 combined Figure 1
Receiver operator characteristic (ROC) curves for 
risk assessment models for BRCA1 and BRCA2 com-
bined.
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overall cost of BRCA genetic testing may ultimately be
affected by the risk model used to determine eligibility.
Although the ROC curve and related statistics are not
affected by mutation prevalence, we anticipated that our
results may suffer from biases related to the characteristics
of the probands in the case-control sample. The possibil-
ity of a selection bias exists because this case-control sam-
ple included only probands who completed BRCA genetic
testing. This selection and the case-control sample struc-
ture can both result in 'spectrum of disease' bias. The
'spectrum of disease' refers to how obvious or hidden the
condition to be detected is among the individuals in the
sample. For the purposes of this study, the 'spectrum of
disease' is used to describe the spectrum of risk of having
a BRCA gene mutation. For example, sensitivity will be
artificially high if one's sample has more probands with a
strong family history of breast and ovarian cancer than the
target population. We characterized the 'spectrum of dis-
ease' by the percentage of probands with none versus one
or more first degree relatives with breast or ovarian cancer,
and found that the results differed substantially for these
two groups (Table 4). To address the possible bias of our
case-control sample, we compared the proportion of
high-risk and low-risk probands from this study to an
unselected population using a tally of all patients referred
to our clinic between May and October 2005. Out of 103
unselected probands referred during this time period,
Table 4: Area under the receiver operating characteristic (ROC) curve with 95% confidence limits
Model Area under the ROC curve (95% confidence limits)
All Low risk subset High risk subset
BRCA status
BRCAPRO 0.76 (0.70 – 0.82) 0.70 (0.57 – 0.81) 0.80 (0.73 – 0.87)
Manchester 0.68 (0.60 – 0.76) 0.57 (0.37 – 0.72) 0.73 (0.63 – 0.81)
Penn II 0.74 (0.67 – 0.80) 0.68 (0.54 – 0.79) 0.77 (0.70 – 0.83)
Myriad II 0.76 (0.71 – 0.82) 0.70 (0.59 – 0.80) 0.80 (0.72 – 0.86)
FHAT 0.74 (0.66 – 0.80) 0.66 (0.55 – 0.76) 0.83 (0.76 – 0.89)
IBIS 0.47 (0.28 – 0.69) - -
BOADICEA 0.74 (0.67 – 0.80) 0.68 (0.56 – 0.79) 0.77 (0.70 – 0.84)
BRCA1 status
BRCAPRO 0.80 (0.72 – 0.87) 0.8 (0.62 – 0.91) 0.81 (0.71 – 0.88)
Manchester 0.78 (0.69 – 0.86) 0.74 (0.46 – 0.93) 0.79 (0.69 – 0.88)
Penn II 0.79 (0.72 – 0.85) 0.76 (0.61 – 0.86) 0.81 (0.73 – 0.87)
COUCH 0.82 (0.75 – 0.87) 0.82 (0.65 – 0.92) 0.84 (0.75 – 0.89)
IBIS 0.43 (0.28 – 0.56) - -
BOADICEA 0.80 (0.72 – 0.86) 0.79 (0.61 – 0.89) 0.80 (0.71 – 0.87)
BRCA2 status
BRCAPRO 0.60 (0.50 – 0.68) 0.57 (0.42 – 0.71) 0.62 (0.48 – 0.73)
Manchester 0.60 (0.49 – 0.70) 0.56 (0.34 – 0.74) 0.63 (0.49 – 0.74)
Penn II 0.57 (0.48 – 0.65) 0.54 (0.39 – 0.69) 0.58 (0.46 – 0.69)
IBIS 0.58 (0.29 – 0.84) - -
BOADICEA 0.63 (0.54 – 0.73) 0.59 (0.41 – 0.76) 0.67 (0.55 – 0.77)
Table 5: Sensitivity and specificity at the conventional thresholds
Model Conventional threshold Sensitivity at conventional threshold Specificity at conventional threshold
All Low risk subset High risk subset All Low risk subset High risk subset
BRCA status
BRCAPRO 10 0.75 0.63 0.82 0.62 0.70 0.58
Manchester 15 0.58 0.39 0.64 0.71 0.73 0.72
Penn II 10 0.93 0.94 0.92 0.31 0.14 0.40
Myriad II 10 0.71 0.66 0.74 0.63 0.65 0.62
FHAT 10 0.70 0.34 0.89 0.63 0.85 0.51
IBIS 10 0.20 - - 0.74 - -
BOADICEA 10 0.70 0.63 0.74 0.65 0.70 0.62BMC Medical Genetics 2008, 9:116 http://www.biomedcentral.com/1471-2350/9/116
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there was a prevalence of 33% low risk probands (no first
degree relatives with breast/ovarian cancer). In the full
case-control sample used in this study, we had a similar
percentage of low-risk probands (35%). This suggests that
the risk assessment models would perform similarly in
this case-control sample and an unselected sample.
We also investigated the effect of having a sample with a
fairly high proportion of Ashkenazi Jewish probands. The
presence of Ashkenazi Jewish probands did not affect the
AUCs greatly. Using knowledge of their own case mix and
judiciously weighing the results, other genetics clinics can
adapt our results to their populations.
These study results are applicable to a familial genetics
program where probands have a personal and/or family
history of cancer, but may not be useful for the general
population. A further limitation of the study is that the
sample size was optimized for the full case-control sam-
ple. Thus the estimates obtained from the subset analyses
are less precise.
Conclusion
A number of factors should be considered when deciding
on the risk assessment models to use in a familial genetics
program. The model should have very high sensitivity,
data should be easy to obtain, data entry should be fast
and efficient, and the model should be applicable to most
patients regardless of cancer status, sex, or degree of cancer
history within the family. In our clinic, the Penn II model
came closest to meeting the above criteria in comparison
to other risk assessment models when the recommended
testing threshold was used.
In our study, we compared all available models, including
BRCAPRO, the newly updated (2007) version of the Penn
II model, and the BOADICEA model that recently became
publicly accessible. We demonstrated that conventional
thresholds may not be appropriate for all models and pur-
poses, and this aspect deserves further study. Providing
information on the spectrum of patients we studied and
giving results separately for low and high risk patients
allow other clinics to apply these results to their patient
populations.
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